<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/328351</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Cancer Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>No effect of administration of unacylated ghrelin on subcutaneous PC3 xenograft growth in a <italic>Rag1</italic><sup>&#x2212;/&#x2212;</sup> mouse model of metabolic dysfunction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Maugham</surname><given-names>Michelle L.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8594-7217</contrib-id>
<name><surname>Seim</surname><given-names>Inge</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3649-7923</contrib-id>
<name><surname>Thomas</surname><given-names>Patrick B.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Crisp</surname><given-names>Gabrielle J.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shah</surname><given-names>Esha T.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Herington</surname><given-names>Adrian C.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brown</surname><given-names>Kristy A.</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gregory</surname><given-names>Laura S.</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nelson</surname><given-names>Colleen C.</given-names></name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jeffery</surname><given-names>Penny L.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">&#x00B6;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chopin</surname><given-names>Lisa K.</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">&#x00B6;</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Ghrelin Research Group, Translational Research Institute - Institute of Health and Biomedical Innovation, Queensland University of Technology</institution>, Brisbane, Queensland, <country>Australia</country>.</aff>
<aff id="a2"><label>2</label><institution>Australian Prostate Cancer Research Centre - Queensland, Translational Research Institute - Institute of Health and Biomedical Innovation, Queensland University of Technology</institution>, Brisbane, Queensland, <country>Australia</country>.</aff>
<aff id="a3"><label>3</label><institution>Comparative and Endocrine Biology Laboratory, Translational Research Institute - Institute of Health and Biomedical Innovation, Queensland University of Technology</institution>, Brisbane, Queensland, <country>Australia</country>.</aff>
<aff id="a4"><label>4</label><institution>Department of Medicine, Weill Cornell Medicine</institution>, New York City, New York, <country>United States of America</country>.</aff>
<aff id="a5"><label>5</label><institution>Skeletal Biology and Forensic Anthropology Research Laboratory, School of Biomedical Sciences, Queensland University of Technology</institution>, Brisbane, Queensland, <country>Australia</country>.</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Corresponding author E-mail: <email>l.chopin@qut.edu.au</email> (L.K.C)</corresp>
<fn id="n1" fn-type="equal"><label>&#x00B6;</label><p>Contributed equally as senior authors.</p></fn>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>328351</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>5</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="328351.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Ghrelin is a peptide hormone which, when acylated, regulates appetite, energy balance and a range of other biological processes. Ghrelin predominately circulates in its unacylated form (unacylated ghrelin; UAG). UAG has a number of functions independent of acylated ghrelin, including modulation of metabolic parameters and cancer progression. UAG has also been postulated to antagonise some of the metabolic effects of acyl-ghrelin, including its effects on glucose and insulin regulation. In this study, <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mice with high-fat diet-induced obesity and hyperinsulinaemia were subcutaneously implanted with PC3 prostate cancer xenografts to investigate the effect of UAG treatment on metabolic parameters and xenograft growth. Daily intraperitoneal injection of 100 &#x03BC;g/kg UAG had no effect on xenograft tumour growth in mice fed normal rodent chow or 23&#x0025; high-fat diet. UAG significantly improved glucose tolerance in host <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mice on a high-fat diet, but did not significantly improve other metabolic parameters. We hypothesise that UAG is not likely to be an effective treatment for prostate cancer, with or without associated metabolic syndrome.</p>
<sec sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare no conflict of interest.</p>
</sec>
</abstract>
<counts>
<page-count count="21"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The peptide hormone ghrelin is a circulating appetite-stimulating hormone which regulates a number of other biological processes [<xref rid="c1" ref-type="bibr">1</xref>&#x2013;<xref rid="c3" ref-type="bibr">3</xref>], including metabolism and energy balance [<xref rid="c1" ref-type="bibr">1</xref>&#x2013;<xref rid="c4" ref-type="bibr">4</xref>], and diseases such as cancer [<xref rid="c5" ref-type="bibr">5</xref>]. Ghrelin acts via its cognate receptor, the growth hormone secretagogue receptor 1a (GHSR1a), a G protein-coupled receptor [<xref rid="c6" ref-type="bibr">6</xref>], and one or more unknown alternative receptors [<xref rid="c7" ref-type="bibr">7</xref>&#x2013;<xref rid="c10" ref-type="bibr">10</xref>]. In order to activate GHSR1a at physiological concentrations, ghrelin must be acylated at its third residue, a serine [<xref rid="c11" ref-type="bibr">11</xref>, <xref rid="c12" ref-type="bibr">12</xref>], by the enzyme ghrelin <italic>O</italic>-acyl transferase (GOAT) [<xref rid="c11" ref-type="bibr">11</xref>, <xref rid="c12" ref-type="bibr">12</xref>].</p>
<p>The major circulating form of ghrelin is its unmodified form, unacylated ghrelin (UAG). UAG, which does not directly stimulate feeding [<xref rid="c5" ref-type="bibr">5</xref>], was initially considered to be functionally inactive, but is now appreciated to bind to and activate a distinct, unknown receptor [<xref rid="c4" ref-type="bibr">4</xref>, <xref rid="c13" ref-type="bibr">13</xref>&#x2013;<xref rid="c18" ref-type="bibr">18</xref>] and have a number of functions [<xref rid="c19" ref-type="bibr">19</xref>&#x2013;<xref rid="c22" ref-type="bibr">22</xref>]. UAG plays roles in the regulation of glucose and energy balance and has effects on cell proliferation [<xref rid="c19" ref-type="bibr">19</xref>&#x2013;<xref rid="c23" ref-type="bibr">23</xref>]. Importantly, it may oppose some of the effects of acyl-ghrelin [<xref rid="c16" ref-type="bibr">16</xref>, <xref rid="c24" ref-type="bibr">24</xref>&#x2013;<xref rid="c26" ref-type="bibr">26</xref>] preventing the rise in circulating glucose and insulin associated with acyl-ghrelin administration in rodents [<xref rid="c22" ref-type="bibr">22</xref>, <xref rid="c27" ref-type="bibr">27</xref>]. From these studies, it is apparent that UAG is an endocrine hormone in its own right [<xref rid="c20" ref-type="bibr">20</xref>]. UAG and the truncated, cyclised UAG analogue AZP-531 prevented the development of pre-diabetes in C57BL/6 mice fed a high-fat diet for two weeks, highlighting a potential of unacylated forms of ghrelin as treatments for metabolic syndrome [<xref rid="c27" ref-type="bibr">27</xref>]. In human trials, UAG had similar effects, improving glycaemic control and insulin sensitivity in patients with type 2 diabetes mellitus [<xref rid="c28" ref-type="bibr">28</xref>] and improving glucose handling and reducing free fatty acids in healthy subjects when administered overnight as a continuous infusion [<xref rid="c29" ref-type="bibr">29</xref>]. AZP-531 also had beneficial effects on glucose balance and led to weight loss in patients with type 2 diabetes mellitus in a phase I clinical trial [<xref rid="c30" ref-type="bibr">30</xref>]. Similar benefits have been observed in patients with Prader-Willi syndrome, a genetic disorder associated with hyperghrelinaemia and obesity [<xref rid="c31" ref-type="bibr">31</xref>].</p>
<p>Close to two decades of work has firmly established a role for the ghrelin axis in cancer [<xref rid="c5" ref-type="bibr">5</xref>, <xref rid="c32" ref-type="bibr">32</xref>&#x2013;<xref rid="c35" ref-type="bibr">35</xref>]. This includes prostate cancer, a classical endocrine-related cancer and the most commonly diagnosed cancer in American men after skin cancer [<xref rid="c36" ref-type="bibr">36</xref>], where acylghrelin increases cell proliferation and migration [<xref rid="c5" ref-type="bibr">5</xref>, <xref rid="c14" ref-type="bibr">14</xref>, <xref rid="c37" ref-type="bibr">37</xref>&#x2013;<xref rid="c46" ref-type="bibr">46</xref>]. UAG also has functional effects in several cancers, including prostate cancer [<xref rid="c5" ref-type="bibr">5</xref>, <xref rid="c32" ref-type="bibr">32</xref>&#x2013;<xref rid="c34" ref-type="bibr">34</xref>, <xref rid="c43" ref-type="bibr">43</xref>]. In the PC3 prostate cancer cell line, UAG has a biphasic effect, reducing cell proliferation at supraphysiological levels (10nM-1&#x03BC;M) [<xref rid="c14" ref-type="bibr">14</xref>].</p>
<p>Studies investigating the role of UAG in prostate cancer have been limited to <italic>in vitro</italic> experiments. <italic>In vivo</italic> studies are required, however, as obesity and overweight and co-morbidities, including hyperinsulinaemia, are now recognised as critical risk factors for numerous cancers [<xref rid="c47" ref-type="bibr">47</xref>&#x2013;<xref rid="c49" ref-type="bibr">49</xref>]. These include cancer types with high-prevalence and mortality, such as tumours of the prostate, endometrium, breast, and gastrointestinal system [<xref rid="c47" ref-type="bibr">47</xref>&#x2013;<xref rid="c55" ref-type="bibr">55</xref>]. Obesity and increased body mass have been associated with increased risk of advanced prostate cancer, more aggressive and high-grade disease and increased risk of death from prostate cancer [<xref rid="c56" ref-type="bibr">56</xref>&#x2013;<xref rid="c59" ref-type="bibr">59</xref>]. Castration-resistant prostate cancer (CRPC) occurs when prostate cancer recurs after remission from androgen-targeted therapies (ATT) [<xref rid="c60" ref-type="bibr">60</xref>]. Treatments for CRPC are limited and this stage of the disease often results in the formation of painful, metastatic bone lesions and associated morbidity and mortality [<xref rid="c61" ref-type="bibr">61</xref>&#x2013;<xref rid="c63" ref-type="bibr">63</xref>]. Metabolic syndrome and hyperinsulinaemia are common side effects of ATT [<xref rid="c64" ref-type="bibr">64</xref>, <xref rid="c65" ref-type="bibr">65</xref>] and may also further accelerate the progression to CRPC [<xref rid="c48" ref-type="bibr">48</xref>, <xref rid="c58" ref-type="bibr">58</xref>, <xref rid="c66" ref-type="bibr">66</xref>&#x2013;<xref rid="c68" ref-type="bibr">68</xref>]. As UAG reduces prostate cancer proliferation <italic>in vitro</italic> [<xref rid="c14" ref-type="bibr">14</xref>] and has potential beneficial metabolic effects <italic>in vivo</italic>, we examined the effect of UAG in our model of metabolic dysfunction: <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mice fed a high-fat diet, with subcutaneous prostate cancer cell line xenografts [<xref rid="c69" ref-type="bibr">69</xref>].</p>
</sec>
<sec id="s2">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Cell Culture</title>
<p>Human prostate cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The PC3 prostate cancer cell line was cultured in Roswell Park Memorial Institute 1640 medium (RPMI-1640) and supplemented with 10&#x0025; (v/v) Fetal Calf serum (FCS) (Thermo Fisher Scientific, Waltham, MA, USA), 50 units/ml penicillin, and 100 &#x03BC;g/mL streptomycin (Thermo Fisher Scientific). Cells were tested negative for <italic>Mycoplasma</italic>.</p>
</sec>
<sec id="s2b">
<title>Hyperinsulinaemic <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mouse model treated with unacylated ghrelin (UAG)</title>
<p>To determine the metabolic effect of UAG in an engraftable mouse model of hyperinsulinaemia [<xref rid="c69" ref-type="bibr">69</xref>], male recombination-activation gene deficient mice (B6.SVJ129-<italic>Rag1<sup>tm1Bal</sup></italic>/Arc; <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic>) (Jackson Laboratories, supplied by Animal Resource Centre, Murdoch, WA, Australia) were weaned onto a diet of low-fat normal chow (LFD) or a Western-style, high-fat diet (HFD; 23&#x0025; fat, SF04-027, Specialty Feeds, WA) [<xref rid="c69" ref-type="bibr">69</xref>]. After two weeks on the diet, mice were subcutaneously injected into the left flank with 1&#x00D7;10<sup>6</sup> PC3 cells diluted 1:1 in growth factor reduced, phenol red-free Matrigel (Corning, NY, USA). Tumours were allowed to grow until a volume of approximately 50-100 mm<sup>3</sup> was reached, when mice were randomly divided into two experimental groups. Mice then received daily intraperitoneal injections of 100 &#x03BC;g/kg UAG (Mimotopes, Mulgrave, Vic, Australia) (<italic><italic>n</italic>&#x003D;6</italic> HFD, <italic>n</italic>&#x003D;10 LFD) (a dose previously determined to inhibit breast cancer growth <italic>in vivo</italic> [<xref rid="c8" ref-type="bibr">8</xref>]) or phosphate buffered saline (PBS) control (<italic>n</italic>&#x003D;8 HFD, <italic>n</italic>&#x003D;10 LFD) for 16 days. Tumour volume was calculated by measuring subcutaneous tumour length and width twice weekly using digital calipers (ProSciTech, Kirwan, QLD, Australia). Tumour volume was calculated using the equation &#x2018;tumour volume &#x003D; (width &#x00D7; length<sup>2</sup>)/2&#x2019; [<xref rid="c70" ref-type="bibr">70</xref>]. Bodyweight was measured twice weekly. At endpoint, tumours and adipose tissue (epididymal fat pad and interscapular brown adipose tissue) were excised and weighed. Fasting blood glucose was measured at endpoint and blood was collected by cardiac puncture for serum biochemical measurements. Surrogate indices of insulin resistance, insulin sensitivity, and steady state &#x03B2;-cell function were determined using the homeostatic model for assessment calculator (HOMA2), available from the Oxford Centre for Diabetes, Endocrinology and Metabolism [<xref rid="c71" ref-type="bibr">71</xref>], using measured fasting glucose and insulin levels.</p>
</sec>
<sec id="s2c">
<title>Statistics</title>
<p>Statistical analyses were performed using GraphPad Prism v.6.01 software (GraphPad Software, Inc., San Diego, CA). Kruskal-Wallis (three or more groups) and Mann-Whitney <italic>U</italic>-test (two groups) tests used for non-normally distributed data, while a two-way ANOVA with Tukey&#x2019;s post-hoc test used for normally distributed data. <italic>P</italic> &#x2264; 0.05 was considered to be statistically significant.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>No effect of intraperitoneal administration of UAG on PC3 xenograft growth in obese, hyperinsulinaemic <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mice</title>
<p>No significant differences in tumour volume over the treatment period or tumour weight (<italic>P</italic>&#x003D;0.57) and volume at endpoint (<italic>P</italic>&#x003D;0.55) were observed between UAG-treated and untreated obese mice (14 days of treatment) (Mann-Whitney test, <xref ref-type="fig" rid="fig1">Fig. 1A-C</xref>). An increase in insulin sensitivity (<italic>P</italic>&#x003D;0.70) and reduction in body weight (<italic>P</italic>&#x003D;0.08), epididymal fat pad weight (<italic>P</italic>&#x003D;0.26), interscapular brown adipose tissue weight (<italic>P</italic>&#x003D;0.12), fasting blood glucose (<italic>P</italic>&#x003D;0.50), fasting blood insulin (<italic>P</italic>&#x003D;0.90), insulin resistance (<italic>P</italic>&#x003D;0.70), and steady-state P-cell function (<italic>P</italic>&#x003D;0.22) was observed in the UAG treatment group in HFD-fed <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mice-however, these changes were not statistically significant (<xref ref-type="fig" rid="fig1">Fig. 1D-L</xref>). There was a significant difference in blood glucose at 30 minutes following glucose challenge in HFD-fed UAG-treated mice compared to PBS controls at endpoint (after 16 days of treatment) (21.6 &#x00B1; 1.2mM, <italic>n</italic>&#x003D;6 vs 25.4 &#x00B1; 1.9mM, <italic>n</italic>&#x003D;5, <italic>P</italic>&#x003D;0.02, two-way ANOVA with post-hoc test, <xref ref-type="fig" rid="fig1">Fig. 1G</xref>), however, this was not observed at other time points, suggesting no major change in glucose tolerance. There was no significant difference in fasting blood glucose (<italic>P</italic>&#x003D;0.50), blood insulin concentration (<italic>P</italic> &#x003D; 0.90, Mann-Whitney test, <xref ref-type="fig" rid="fig1">Fig. 1I</xref>), insulin resistance (<italic>P</italic> &#x003D; 0.70, Mann-Whitney test, <xref ref-type="fig" rid="fig1">Fig. 1J</xref>), or insulin sensitivity (<italic><italic>P</italic>&#x003D;0.70</italic>, Mann-Whitney test, <xref ref-type="fig" rid="fig1">Fig. 1L</xref>).</p>
<fig id="fig1" position="float" fig-type="figure">
<label>Fig. 1.</label>
<caption><title>Unacylated ghrelin (UAG) affects glucose tolerance but has no effect on tumour volume or on other metabolic parameters.</title>
<p><italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mice fed a 23&#x0025; high-fat diet (HFD) or low-fat diet (LFD) were injected with subcutaneous PC3 xenografts and administered UAG (100&#x03BC;g/kg/day, i.p.) (<italic>n</italic>&#x003D;6 HFD, <italic>n</italic>&#x003D;10 LFD) or PBS control (<italic>n</italic>&#x003D;8 HFD, <italic>n</italic>&#x003D;10 LFD) once tumours were palpable. Mean &#x00B1; s.e.m. &#x002A; <italic>P</italic>&#x2264;0.05. (A) Tumour volume (mm<sup>3</sup>) measured over time (<italic>P</italic>&#x003D;0.57), (B) tumour volume (mm<sup>3</sup>) (<italic>P</italic>&#x003D;0.55) and (C) tumour weight (g) measured at experimental endpoint were not significantly different between UAG&#x002D; and PBS-treated mice fed HFD or LFD. Mean &#x00B1; s.e.m. Mann-Whitney test. (D) Body weight (g) of mice at endpoint (<italic>P</italic>&#x003D;0.08), (E) epididymal fat pad weight (g) (<italic>P</italic>&#x003D;0.26) and (F) interscapular brown adipose tissue weight (g) (<italic>P</italic>&#x003D;0.12) were not significantly different in UAG-treated mice compared to PBS-treated mice. Mean &#x00B1; s.e.m. Mann-Whitney test. (G) HFD-fed UAG-treated mice (<italic>n</italic>&#x003D;6) had significantly lower blood glucose 30 min post-glucose challenge compared to HFD-fed PBS treated mice (<italic>n</italic>&#x003D;8), determined by intraperitoneal glucose tolerance test (IPGTT). Mean &#x00B1; s.e.m. Two-way ANOVA. &#x002A; <italic>P</italic>&#x003D;0.025. (H) Fasting blood glucose (mM) (<italic>P</italic>&#x003D;0.50) and (I) fasting blood insulin (ng/ml) were not altered in UAG-treated compared to PBS-treated mice on either diet. Mean &#x00B1; s.e.m. <italic>P</italic>&#x003D;0.90. Mann-Whitney test. (J) Insulin resistance (HOMA-IR) (<italic>P</italic>&#x003D;0.70), (K) steady state &#x03B2;-cell function (HOMA&#x0025;B) (<italic>P</italic>&#x003D;0.22) and (L) insulin sensitivity (HOMA&#x0025;S) (<italic>P</italic>&#x003D;0.70) were not altered in UAG-treated compared to PBS-treated mice on either diet. Mean &#x00B1; s.e.m. Mann-Whitney test.</p></caption>
<graphic xlink:href="328351_fig1.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>It has recently been recognised that UAG can under some conditions act as a functional ghrelin inhibitor, reducing ghrelin-mediated increases in plasma glucose [<xref ref-type="bibr" rid="c22">22</xref>, <xref ref-type="bibr" rid="c26">26</xref>, <xref ref-type="bibr" rid="c28">28</xref>, <xref ref-type="bibr" rid="c72">72</xref>] and lipid [<xref rid="c27" ref-type="bibr">27</xref>, <xref rid="c29" ref-type="bibr">29</xref>]. As the ghrelin axis also plays a role in the progression of a number of endocrine-related cancers [<xref rid="c5" ref-type="bibr">5</xref>, <xref rid="c32" ref-type="bibr">32</xref>&#x2013;<xref rid="c34" ref-type="bibr">34</xref>], including prostate cancer [<xref rid="c5" ref-type="bibr">5</xref>, <xref rid="c43" ref-type="bibr">43</xref>], we hypothesised that UAG may have beneficial effects in advanced prostate cancer associated with metabolic syndrome. To evaluate this hypothesis, we examined the effect of UAG on a prostate cancer cell line <italic>in vivo</italic>.</p>
<p>In our diet-induced hyperinsulinaemic <italic>Rag1<sup>&#x2212;/&#x2212;</sup></italic> mouse model [<xref rid="c69" ref-type="bibr">69</xref>], we investigated the effect of supraphysiological systemic UAG treatment (100&#x03BC;g/kg/day) on metabolic parameters and PC3 prostate cancer xenograft growth. No differences in metabolic parameters (fasting blood glucose, fasting blood insulin, insulin resistance, steady-state &#x03B2;-cell function, and insulin sensitivity) were observed with UAG treatment in HFD-fed mice. Other studies have found that UAG prevents insulin resistance and hyperglycaemia in short-term HFD-fed mice [<xref rid="c73" ref-type="bibr">73</xref>], observations which may stem from the ability of UAG to cross the blood-brain barrier and oppose the central actions of ghrelin on energy homeostasis [<xref rid="c74" ref-type="bibr">74</xref>]. Furthermore, in human clinical trials UAG improved glucose and lipid metabolism in healthy [<xref rid="c29" ref-type="bibr">29</xref>] and diabetic patients [<xref rid="c28" ref-type="bibr">28</xref>]. In our study, a decrease in bodyweight, epididymal fat pad weight, and interscapular brown adipose tissue was observed in HFD-fed UAG treated mice but this difference was not statistically significant. UAG did significantly reduce blood glucose levels at 30 minutes post-glucose challenge in HFD, but not LFD-fed mice, however. This is similar to other studies, which have only found positive effects of UAG on glucose tolerance in obese patients [<xref rid="c72" ref-type="bibr">72</xref>]. Similarly, in clinical trials, AZP-531 (a cyclised, truncated analogue of UAG) improved food-related behaviour, waist circumference, and glucose tolerance in Prader-Willi syndrome patients, but had no effect on body weight [<xref rid="c31" ref-type="bibr">31</xref>]. AZP-531 also prevents HFD-induced weight gain, insulin resistance, and impairment of glucose tolerance in mice [<xref rid="c27" ref-type="bibr">27</xref>].</p>
<p>To the best of our knowledge, this is the first report on the effects of UAG on cancer cell line xenograft growth <italic>in vivo</italic>. While our study and others show somewhat promising effects of UAG treatment on metabolic parameters, systemic UAG administration had no effect on prostate tumour xenograft size in mice fed a low-fat or high-fat diet. While preliminary, our study suggests that UAG administration, or targeting of endocrine UAG, may have limited therapeutic potential for prostate cancer, in patients with and without symptoms of metabolic syndrome.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by the National Health and Medical Research Council Australia (grant no. 1002255 and 1059021 to PLJ, LKC, ACH, and IS), the Cancer Council Queensland (grant no. 1098565 to LKC, ACH, and IS), the Australian Research Council (grant no DP140100249 to LKC and ACH), a QUT Vice-Chancellor&#x2019;s Senior Research Fellowship (to IS), the Movember Foundation and the Prostate Cancer Foundation of Australia through a Movember Revolutionary Team Award, the Australian Government Department of Health, and the Australian Prostate Cancer Research Center, Queensland (LKC, ACH, and CCN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Wren</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Seal</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Brynes</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Frost</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Murphy</surname> <given-names>KG</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin enhances appetite and increases food intake in humans</article-title>. <source>J. Clin Endocrinol. Metab.</source> <year>2001</year>;<volume>86</volume>(<issue>12</issue>): <fpage>5992</fpage>. doi: <pub-id pub-id-type="doi">10.1210/jcem.86.12.8111</pub-id>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Tschop</surname> <given-names>M</given-names></string-name>, <string-name><surname>Smiley</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Heiman</surname> <given-names>ML</given-names></string-name>. <article-title>Ghrelin induces adiposity in rodents</article-title>. <source>Nature</source>. <year>2000</year>;<volume>407</volume>(<issue>6806</issue>): <fpage>908</fpage>&#x2013;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1038/35038090</pub-id>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Tschop</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wawarta</surname> <given-names>R</given-names></string-name>, <string-name><surname>Riepl</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Friedrich</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bidlingmaier</surname> <given-names>M</given-names></string-name>, <string-name><surname>Landgraf</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title>Post-prandial decrease of circulating human ghrelin levels</article-title>. <source>J. Endocrinol. Invest</source>. <year>2001</year>;<volume>24</volume>(<issue>6</issue>): <fpage>RC19</fpage>&#x2013;<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Toshinai</surname> <given-names>K</given-names></string-name>, <string-name><surname>Mondal</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Nakazato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Date</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Murakami</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kojima</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <year>2001</year>;<volume>281</volume>(<issue>5</issue>): <fpage>1220</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1006/bbrc.2001.4518</pub-id>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Chopin</surname> <given-names>LK</given-names></string-name>, <string-name><surname>Seim</surname> <given-names>I</given-names></string-name>, <string-name><surname>Walpole</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Herington</surname> <given-names>AC</given-names></string-name>. <article-title>The ghrelin axis&#x002D;-does it have an appetite for cancer progression?</article-title> <source>Endocrine Rev.</source> <year>2012</year>;<volume>33</volume>(<issue>6</issue>): <fpage>849</fpage> &#x2013; <lpage>91</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Kojima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hosoda</surname> <given-names>H</given-names></string-name>, <string-name><surname>Date</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Nakazato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Matsuo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kangawa</surname> <given-names>K</given-names></string-name>. <article-title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach</article-title>. <source>Nature</source>. <year>1999</year>;<volume>402</volume>(<issue>6762</issue>): <fpage>656</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1038/45230</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Chopin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Walpole</surname> <given-names>C</given-names></string-name>, <string-name><surname>Seim</surname> <given-names>I</given-names></string-name>, <string-name><surname>Cunningham</surname> <given-names>P</given-names></string-name>, <string-name><surname>Murray</surname> <given-names>R</given-names></string-name>, <string-name><surname>Whiteside</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin and cancer</article-title>. <source>Mol. Cell. Endocrinol.</source> <year>2011</year>;<volume>340</volume>(<issue>1</issue>): <fpage>65</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mce.2011.04.013</pub-id>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>CheukMan Cherie</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kara</surname> <given-names>LB</given-names></string-name>, <string-name><surname>Maria</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Brid</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jason</surname> <given-names>EC</given-names></string-name>, <string-name><surname>John</surname> <given-names>BF</given-names></string-name>, <etal>et al.</etal> <article-title>Des-acyl ghrelin suppresses breast cancer cell growth in vitro and in vivo</article-title>. <source>Meeting Abstracts: Endocrine Society</source>; <year>2016</year>. p. <fpage>FRI</fpage>&#x2013;<lpage>065</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Docanto</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Callaghan</surname> <given-names>B</given-names></string-name>, <string-name><surname>Au</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Ragavan</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism</article-title>. <source>Breast Cancer Res. Treat</source>. <year>2014</year>;<volume>147</volume>(<issue>1</issue>): <fpage>193</fpage>&#x2013;<lpage>201</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10549-014-3060-1</pub-id>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Callaghan</surname> <given-names>B</given-names></string-name>, <string-name><surname>Furness</surname> <given-names>JB</given-names></string-name>. <article-title>Novel and conventional receptors for ghrelin, desacyl-ghrelin, and pharmacologically related compounds</article-title>. <source>Pharmacol. Rev.</source> <year>2014</year>;<volume>66</volume>(<issue>4</issue>):<fpage>984</fpage>&#x2013;<lpage>1001</lpage>. doi: <pub-id pub-id-type="doi">10.1124/pr.113.008433</pub-id>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Goldstein</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>MS</given-names></string-name>. <article-title>Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <year>2008</year>;<volume>105</volume>(<issue>31</issue>): <fpage>10750</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0805353105</pub-id>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Gutierrez</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Solenberg</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Perkins</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Willency</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Knierman</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>Z</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin octanoylation mediated by an orphan lipid transferase</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <year>2008</year>;<volume>105</volume>(<issue>17</issue>): <fpage>6320</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0800708105</pub-id>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Baldanzi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Filigheddu</surname> <given-names>N</given-names></string-name>, <string-name><surname>Cutrupi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Catapano</surname> <given-names>F</given-names></string-name>, <string-name><surname>Bonissoni</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fubini</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT</article-title>. <source>J. Cell Biol.</source> <year>2002</year>;<volume>159</volume>(<issue>6</issue>):<fpage>1029</fpage>&#x2013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1083/jcb.200207165</pub-id>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Cassoni</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ghe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Marrocco</surname> <given-names>T</given-names></string-name>, <string-name><surname>Tarabra</surname> <given-names>E</given-names></string-name>, <string-name><surname>Allia</surname> <given-names>E</given-names></string-name>, <string-name><surname>Catapano</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title>Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines</article-title>. <source>Eur. J. Endocrinol.</source> <year>2004</year>;<volume>150</volume>(<issue>2</issue>): <fpage>173</fpage>&#x2013;<lpage>84</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Cassoni</surname> <given-names>P</given-names></string-name>, <string-name><surname>Papotti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ghe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Catapano</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sapino</surname> <given-names>A</given-names></string-name>, <string-name><surname>Graziani</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <year>2001</year>;<volume>86</volume>(<issue>4</issue>): <fpage>1738</fpage>&#x2013;<lpage>45</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Gauna</surname> <given-names>C</given-names></string-name>, <string-name><surname>Delhanty</surname> <given-names>PJD</given-names></string-name>, <string-name><surname>Hofland</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Janssen</surname> <given-names>JAMJL</given-names></string-name>, <string-name><surname>Broglio</surname> <given-names>F</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>RJM</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin Stimulates, Whereas Des-Octanoyl Ghrelin Inhibits, Glucose Output by Primary Hepatocytes</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <year>2005</year>;<volume>90</volume>(<issue>2</issue>): <fpage>1055</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Toshinai</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yamaguchi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Yamanaka</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sakurai</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>5</issue>): <fpage>2306</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1210/en.2005-1357</pub-id>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Filigheddu</surname> <given-names>N</given-names></string-name>, <string-name><surname>Gnocchi</surname> <given-names>VF</given-names></string-name>, <string-name><surname>Coscia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cappelli</surname> <given-names>M</given-names></string-name>, <string-name><surname>Porporato</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Taulli</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells</article-title>. <source>Mol. Biol. Cell</source> <year>2007</year>;<volume>18</volume>(<issue>3</issue>): <fpage>986</fpage>&#x2013;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1091/mbc.E06-05-0402</pub-id>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Delhanty</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>van der Eerden</surname> <given-names>BC</given-names></string-name>, <string-name><surname>van der Velde</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gauna</surname> <given-names>C</given-names></string-name>, <string-name><surname>Pols</surname> <given-names>HA</given-names></string-name>, <string-name><surname>Jahr</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a</article-title>. <source>J. Endocrinol.</source> <year>2006</year>;<volume>188</volume>(<issue>1</issue>): <fpage>37</fpage>&#x2013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1677/joe.1.06404</pub-id>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Delhanty</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Visser</surname> <given-names>JA</given-names></string-name>, <string-name><surname>van Kerkwijk</surname> <given-names>A</given-names></string-name>, <string-name><surname>Huisman</surname> <given-names>M</given-names></string-name>, <string-name><surname>van Ijcken</surname> <given-names>WF</given-names></string-name>, <etal>et al.</etal> <article-title>Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice</article-title>. <source>PloS one</source>. <year>2010</year>;<volume>5</volume>(<issue>7</issue>): <fpage>e11749</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0011749</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Baragli</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ghe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Arnoletti</surname> <given-names>E</given-names></string-name>, <string-name><surname>Granata</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ghigo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Muccioli</surname> <given-names>G</given-names></string-name>. <article-title>Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase gamma and phosphodiesterase 3B</article-title>. <source>Biochim. Biophys. Acta.</source> <year>2011</year>;<volume>1811</volume>(<issue>6</issue>): <fpage>386</fpage>&#x2013;<lpage>96</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Broglio</surname> <given-names>F</given-names></string-name>, <string-name><surname>Gottero</surname> <given-names>C</given-names></string-name>, <string-name><surname>Prodam</surname> <given-names>F</given-names></string-name>, <string-name><surname>Gauna</surname> <given-names>C</given-names></string-name>, <string-name><surname>Muccioli</surname> <given-names>G</given-names></string-name>, <string-name><surname>Papotti</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <year>2004</year>;<volume>89</volume>(<issue>6</issue>): <fpage>3062</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1210/jc.2003-031964</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Au</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Docanto</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Zahid</surname> <given-names>H</given-names></string-name>, <string-name><surname>Raffaelli</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Ferrero</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Furness</surname> <given-names>JB</given-names></string-name>, <etal>et al.</etal> <article-title>Des-acyl ghrelin inhibits the capacity of macrophages to stimulate the expression of aromatase in breast adipose stromal cells</article-title>. <source>J. Steroid Biochem. Mol. Biol.</source> <year>2017</year>;<volume>170</volume>: <fpage>49</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jsbmb.2016.07.005</pub-id>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Kumar</surname> <given-names>R</given-names></string-name>, <string-name><surname>Salehi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Rehfeld</surname> <given-names>JF</given-names></string-name>, <string-name><surname>H&#x00F6;glund</surname> <given-names>P</given-names></string-name>, <string-name><surname>Lindstr&#x00F6;m</surname> <given-names>E</given-names></string-name>, <string-name><surname>H&#x00E5;kanson</surname> <given-names>R</given-names></string-name>. <article-title>Proghrelin peptides: Desacyl ghrelin is a powerful inhibitor of acylated ghrelin, likely to impair physiological effects of acyl ghrelin but not of obestatin: A study of pancreatic polypeptide secretion from mouse islets</article-title>. <source>Reg. Peptides.</source> <year>2010</year>;<volume>164</volume>(<issue>2&#x2013;3</issue>): <fpage>65</fpage>&#x2013;<lpage>70</lpage>. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.10167j.regpep.2010.06.005">http://doi.org/10.10167j.regpep.2010.06.005</ext-link>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Neary</surname> <given-names>NM</given-names></string-name>, <string-name><surname>Druce</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Small</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Bloom</surname> <given-names>SR</given-names></string-name>. <article-title>Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect</article-title>. <source>Gut.</source> <year>2006</year>;<volume>55</volume>(<issue>1</issue>): <fpage>135</fpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Gauna</surname> <given-names>C</given-names></string-name>, <string-name><surname>Meyler</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Janssen</surname> <given-names>JAMJL</given-names></string-name>, <string-name><surname>Delhanty</surname> <given-names>PJD</given-names></string-name>, <string-name><surname>Abribat</surname> <given-names>T</given-names></string-name>, <string-name><surname>van Koetsveld</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title>Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <year>2004</year>;<volume>89</volume>(<issue>10</issue>): <fpage>5035</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1210/jc.2004-0363</pub-id>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Delhanty</surname> <given-names>PJ</given-names></string-name>, <string-name><surname>Huisman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baldeon-Rojas</surname> <given-names>LY</given-names></string-name>, <string-name><surname>van den Berge</surname> <given-names>I</given-names></string-name>, <string-name><surname>Grefhorst</surname> <given-names>A</given-names></string-name>, <string-name><surname>Abribat</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis</article-title>. <source>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</source>. <year>2013</year>;<volume>27</volume>(<issue>4</issue>):<fpage>1690</fpage>&#x2013;<lpage>700</lpage>. Epub <date-in-citation content-type="access-date">2013/01/10</date-in-citation>. doi: <pub-id pub-id-type="doi">10.1096/fj.12-221143</pub-id>. <pub-id pub-id-type="pmid">PubMed PMID: 23299855</pub-id>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Ozcan</surname> <given-names>B</given-names></string-name>, <string-name><surname>Neggers</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Miller</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Lucaites</surname> <given-names>V</given-names></string-name>, <string-name><surname>Abribat</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?</article-title> <source>European journal of endocrinology / European Federation of Endocrine Societies</source>. <year>2014</year>;<volume>170</volume>(<issue>6</issue>):<fpage>799</fpage>&#x2013;<lpage>807</lpage>. Epub <date-in-citation content-type="access-date">2013/07/19</date-in-citation>. doi: <pub-id pub-id-type="doi">10.1530/eje-13-0347</pub-id>. <pub-id pub-id-type="pmid">PubMed PMID: 23864339</pub-id>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Benso</surname> <given-names>A S-PD</given-names></string-name>, <string-name><surname>Prodam</surname> <given-names>F</given-names></string-name>, <string-name><surname>Gramaglia</surname> <given-names>E</given-names></string-name>, <string-name><surname>Granata</surname> <given-names>R</given-names></string-name>, <string-name><surname>van der Lely</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Ghigo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Broglio</surname> <given-names>F</given-names></string-name>. <article-title>Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans</article-title>. <source>Eur J Endocrinol</source> <year>2012</year>;<volume>166</volume>(<issue>5</issue>): <fpage>911</fpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Allas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Delale</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ngo</surname> <given-names>N</given-names></string-name>, <string-name><surname>Julien</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sahakian</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ritter</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes</article-title>. <source>Diabetes, Obesity Metab.</source> <year>2016</year>;<volume>18</volume>(<issue>9</issue>): <fpage>868</fpage>&#x2013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1111/dom.12675</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Allas</surname> <given-names>S</given-names></string-name>, <string-name><surname>Caix&#x00E0;s</surname> <given-names>A</given-names></string-name>, <string-name><surname>Poitou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Coupaye</surname> <given-names>M</given-names></string-name>, <string-name><surname>Thuilleaux</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lorenzini</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title>AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial</article-title>. <source>PloS one</source>. <year>2018</year>;<volume>13</volume>(<issue>1</issue>): <fpage>e0190849</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0190849</pub-id>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Fung</surname> <given-names>JNT</given-names></string-name>, <string-name><surname>Jeffery</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Seim</surname> <given-names>I</given-names></string-name>, <string-name><surname>Roche</surname> <given-names>D</given-names></string-name>, <string-name><surname>Obermair</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo</article-title>. <source>Am. J. Physiol.</source> <year>2013</year>;<volume>305</volume>(<issue>2</issue>): <fpage>E305</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Lin</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Hsiao</surname> <given-names>M</given-names></string-name>. <article-title>Ghrelin and cancer progression</article-title>. <source>Biochim. Biophys. Acta.</source> <year>2017</year>;<volume>1868</volume>(<issue>1</issue>): <fpage>51</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbcan.2017.02.002</pub-id>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Gr&#x00F6;nberg</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ahlin</surname> <given-names>C</given-names></string-name>, <string-name><surname>Naeser</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Janson</surname> <given-names>ET</given-names></string-name>, <string-name><surname>Holmberg</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fj&#x00E4;llskog</surname> <given-names>M-L</given-names></string-name>. <article-title>Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer</article-title>. <source>PloS one</source>. <year>2017</year>;<volume>12</volume>(<issue>4</issue>):<fpage>e0176059</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0176059</pub-id>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Yao</surname> <given-names>J</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>R</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Jia</surname> <given-names>M</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>. <article-title>Ghrelin promotes human non-small cell lung cancer A549 cell proliferation through PI3K/Akt/mTOR/P70S6K and ERK signaling pathways</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <year>2018</year>;<volume>498</volume>(<issue>3</issue>): <fpage>616</fpage>&#x2013;<lpage>20</lpage>. doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016Zj.bbrc.2018.03.031">https://doi.org/10.1016Zj.bbrc.2018.03.031</ext-link>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><article-title>American Cancer Society</article-title>. <source>Cancer Facts &#x0026; Figures 2018. Atlanta: American Cancer Society</source>; <year>2018</year>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Bertaccini</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pernetti</surname> <given-names>R</given-names></string-name>, <string-name><surname>Marchiori</surname> <given-names>D</given-names></string-name>, <string-name><surname>Pagotto</surname> <given-names>U</given-names></string-name>, <string-name><surname>Palladoro</surname> <given-names>F</given-names></string-name>, <string-name><surname>Palmieri</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal> <article-title>Variations in blood ghrelin levels in prostate cancer patients submitted to hormone suppressive treatment</article-title>. <source>Anticancer Res.</source> <year>2009</year>;<volume>29</volume>(<issue>4</issue>): <fpage>1345</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Mungan</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Eminferzane</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mungan</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Yesilli</surname> <given-names>C</given-names></string-name>, <string-name><surname>Seckiner</surname> <given-names>I</given-names></string-name>, <string-name><surname>Can</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Diagnostic value of serum ghrelin levels in prostate cancer</article-title>. <source>Urologia internationalis</source>. <year>2008</year>;<volume>80</volume>(<issue>3</issue>):<fpage>245</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000127334</pub-id>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Malendowicz</surname> <given-names>W</given-names></string-name>, <string-name><surname>Ziolkowska</surname> <given-names>A</given-names></string-name>, <string-name><surname>Szyszka</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kwias</surname> <given-names>Z</given-names></string-name>. <article-title>Elevated blood active ghrelin and unaltered total ghrelin and obestatin concentrations in prostate carcinoma</article-title>. <source>Urologia internationalis</source>. <year>2009</year>;<volume>83</volume>(<issue>4</issue>): <fpage>471</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000251190</pub-id>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Jeffery</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Herington</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Chopin</surname> <given-names>LK</given-names></string-name>. <article-title>Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines</article-title>. <source>J. Endocrinol.</source> <year>2002</year>;<volume>172</volume>(<issue>3</issue>): <fpage>R7</fpage>&#x2013;<lpage>R11</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Yeh</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Jeffery</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Duncan</surname> <given-names>RP</given-names></string-name>, <string-name><surname>Herington</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Chopin</surname> <given-names>LK</given-names></string-name>. <article-title>Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer</article-title>. <source>Clin. Cancer Res.</source> <year>2005</year>;<volume>11</volume>(<issue>23</issue>): <fpage>8295</fpage>&#x2013;<lpage>303</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Lanfranco</surname> <given-names>F</given-names></string-name>, <string-name><surname>Baldi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cassoni</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bosco</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ghe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Muccioli</surname> <given-names>G</given-names></string-name>. <article-title>Ghrelin and prostate cancer</article-title>. <source>Vitamins Hormones.</source> <year>2008</year>;<volume>77</volume>: <fpage>301</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0083-6729(06)77013-3</pub-id>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Seim</surname> <given-names>I</given-names></string-name>, <string-name><surname>Jeffery</surname> <given-names>PL</given-names></string-name>, <string-name><surname>de Amorim</surname> <given-names>L</given-names></string-name>, <string-name><surname>Walpole</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Fung</surname> <given-names>J</given-names></string-name>, <string-name><surname>Whiteside</surname> <given-names>EJ</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin O-acyltransferase (GOAT) is expressed in prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin</article-title>. <source>Repro. Biol. Endocrinol.</source> <year>2013</year>;<volume>11</volume>(<issue>1</issue>): <fpage>70</fpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Duxbury</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Waseem</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>H</given-names></string-name>, <string-name><surname>Robinson</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Zinner</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Ashley</surname> <given-names>SW</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <year>2003</year>;<volume>309</volume>(<issue>2</issue>): <fpage>464</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Waseem</surname> <given-names>T</given-names></string-name>, <string-name><surname>Duxbury</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ashley</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Robinson</surname> <given-names>MK</given-names></string-name>. <article-title>Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways</article-title>. <source>Surgery</source>. <year>2008</year>;<volume>143</volume>(<issue>3</issue>): <fpage>334</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.surg.2007.09.039</pub-id>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Dixit</surname> <given-names>VD</given-names></string-name>, <string-name><surname>Weeraratna</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bertak</surname> <given-names>D</given-names></string-name>, <string-name><surname>Cooper-Jenkins</surname> <given-names>A</given-names></string-name>, <string-name><surname>Riggins</surname> <given-names>GJ</given-names></string-name>, <etal>et al.</etal> <article-title>Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility</article-title>. <source>J. Biol. Chem.</source> <year>2006</year>;<volume>281</volume>(<issue>24</issue>): <fpage>16681</fpage>&#x2013;<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M600223200</pub-id>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Hammarsten</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hogstedt</surname> <given-names>B</given-names></string-name>. <article-title>Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer</article-title>. <source>Eur. J. Cancer</source> <year>2005</year>;<volume>41</volume>(<issue>18</issue>): <fpage>2887</fpage>&#x2013;<lpage>95</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2005.09.003</pub-id>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Ma</surname> <given-names>J</given-names></string-name>, <string-name><surname>Li</surname> <given-names>H</given-names></string-name>, <string-name><surname>Giovannucci</surname> <given-names>E</given-names></string-name>, <string-name><surname>Mucci</surname> <given-names>L</given-names></string-name>, <string-name><surname>Qiu</surname> <given-names>W</given-names></string-name>, <string-name><surname>Nguyen</surname> <given-names>PL</given-names></string-name>, <etal>et al.</etal> <article-title>Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis</article-title>. <source>The Lancet Oncology</source>. <year>2008</year>;<volume>9</volume>(<issue>11</issue>): <fpage>1039</fpage>&#x2013;<lpage>47</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1470-2045(08)70235-3</pub-id>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Brooke</surname> <given-names>Steele</given-names></string-name>, <string-name><given-names>Cheryll C.</given-names> <surname>Thomas</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jane Henley</surname></string-name>, <string-name><given-names>Greta M.</given-names> <surname>Massetti</surname></string-name>, <string-name><given-names>Deborah A.</given-names> <surname>Galuska</surname></string-name>, <string-name><given-names>Tanya</given-names> <surname>Agurs-Collins</surname></string-name>, <etal>et al.</etal> <article-title>Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity &#x2014; United States, 2005-2014 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2017</article-title>. <source>MMWR Morb. Mort. Wkly Rep.</source> <year>2017</year>; <volume>66</volume>(<issue>39</issue>):<fpage>1052</fpage>&#x2013;<lpage>1058</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Souaze</surname> <given-names>F</given-names></string-name>, <string-name><surname>Dupouy</surname> <given-names>S</given-names></string-name>, <string-name><surname>Viardot-Foucault</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bruyneel</surname> <given-names>E</given-names></string-name>, <string-name><surname>Attoub</surname> <given-names>S</given-names></string-name>, <string-name><surname>Gespach</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression</article-title>. <source>Cancer Res.</source> <year>2006</year>;<volume>66</volume>(<issue>12</issue>): <fpage>6243</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.can-06-0450</pub-id>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Cui</surname> <given-names>H</given-names></string-name>. <article-title>Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells</article-title>. <source>Mol. Cell. Bioechem.</source> <year>2014</year>;<volume>389</volume>(<issue>1&#x2013;2</issue>): <fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11010-013-1920-3</pub-id>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Brown</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vale</surname> <given-names>W</given-names></string-name>. <article-title>Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels</article-title>. <source>Endocrinology</source>. <year>1976</year>;<volume>98</volume>(<issue>3</issue>): <fpage>819</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1210/endo-98-3-819</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Sehgal</surname> <given-names>I</given-names></string-name>, <string-name><surname>Powers</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huntley</surname> <given-names>B</given-names></string-name>, <string-name><surname>Powis</surname> <given-names>G</given-names></string-name>, <string-name><surname>Pittelkow</surname> <given-names>M</given-names></string-name>, <string-name><surname>Maihle</surname> <given-names>NJ</given-names></string-name>. <article-title>Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>. <year>1994</year>;<volume>91</volume>(<issue>11</issue>): <fpage>4673</fpage>&#x2013;<lpage>7</lpage>. Epub <date-in-citation content-type="access-date">1994/05/24</date-in-citation>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Vias</surname> <given-names>M</given-names></string-name>, <string-name><surname>Burtt</surname> <given-names>G</given-names></string-name>, <string-name><surname>Culig</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Veerakumarasivam</surname> <given-names>A</given-names></string-name>, <string-name><surname>Neal</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Mills</surname> <given-names>IG</given-names></string-name>. <article-title>A role for neurotensin in bicalutamide resistant prostate cancer cells</article-title>. <source>The Prostate</source>. <year>2007</year>;<volume>67</volume>(<issue>2</issue>): <fpage>190</fpage>&#x2013;<lpage>202</lpage>. doi: <pub-id pub-id-type="doi">10.1002/pros.20518</pub-id>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Vidal Samuel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Rodriguez-Bravo</surname> <given-names>V</given-names></string-name>, <string-name><surname>Quinn</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Rodriguez-Barrueco</surname> <given-names>R</given-names></string-name>, <string-name><surname>Lujambio</surname> <given-names>A</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer</article-title>. <source>Cancer Cell</source>. <year>2015</year>;<volume>27</volume>(<issue>2</issue>): <fpage>223</fpage>&#x2013;<lpage>39</lpage>. doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccell.2014.11.013">http://dx.doi.org/10.1016/j.ccell.2014.11.013</ext-link>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Perez-Cornago</surname> <given-names>A</given-names></string-name>, <string-name><surname>Key</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Fensom</surname> <given-names>GK</given-names></string-name>, <string-name><surname>Bradbury</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>RM</given-names></string-name>, <etal>et al.</etal> <article-title>Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study</article-title>. <source>British J. Cancer</source>. <year>2017</year>;<volume>117</volume>: <fpage>1562</fpage>. doi: <pub-id pub-id-type="doi">10.1038/bjc.2017.312</pub-id></mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Discacciati</surname> <given-names>A</given-names></string-name>, <string-name><surname>Orsini</surname> <given-names>N</given-names></string-name>, <string-name><surname>Wolk</surname> <given-names>A</given-names></string-name>. <article-title>Body mass index and incidence of localized and advanced prostate cancer&#x002D;-a dose-response meta-analysis of prospective studies</article-title>. <source>Annals Oncol.</source> <year>2012</year>;<volume>23</volume>(<issue>7</issue>):<fpage>1665</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdr603</pub-id>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Gunter</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Sarkar</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Lubik</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Nelson</surname> <given-names>CC</given-names></string-name>. <article-title>New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication</article-title>. <source>International journal of cell biology</source>. <year>2013</year>;<volume>2013</volume>: <fpage>834684</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2013/834684</pub-id>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><source>World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer</source>. <year>2014</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf">www.wcrf.org/sites/default/files/Prostate-Cancer-2014-Report.pdf</ext-link></mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Grayhack</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Keeler</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Kozlowski</surname> <given-names>JM</given-names></string-name>. <article-title>Carcinoma of the prostate</article-title>. <source>Hormonal therapy. Cancer</source>. <year>1987</year>;<volume>60</volume>(<issue>3 Suppl</issue>): <fpage>589</fpage>&#x2013;<lpage>601</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Vela</surname> <given-names>I</given-names></string-name>, <string-name><surname>Gregory</surname> <given-names>LS</given-names></string-name>, <string-name><surname>Gardiner</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Clements</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Nicol</surname> <given-names>DL</given-names></string-name>. <article-title>Bone and prostate cancer cell interactions in metastatic prostate cancer</article-title>. <source>BJU International</source>. <year>2007</year>;<volume>99</volume>(<issue>4</issue>): <fpage>735</fpage>&#x2013;<lpage>42</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Loberg</surname> <given-names>RD</given-names></string-name>, <string-name><surname>Gayed</surname> <given-names>BA</given-names></string-name>, <string-name><surname>Olson</surname> <given-names>KB</given-names></string-name>, <string-name><surname>Pienta</surname> <given-names>KJ</given-names></string-name>. <article-title>A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions</article-title>. <source>J. Cell Biol.</source> <year>2005</year>;<volume>96</volume>(<issue>3</issue>): <fpage>439</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jcb.20522</pub-id>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Sturge</surname> <given-names>J</given-names></string-name>, <string-name><surname>Caley</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Waxman</surname> <given-names>J</given-names></string-name>. <article-title>Bone metastasis in prostate cancer: emerging therapeutic strategies</article-title>. <source>Nature Rev. Clin. Oncol.</source> <year>2011</year>;<volume>8</volume>:<fpage>357</fpage>&#x2013;<lpage>68</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrclinonc.2011.67</pub-id>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Senmaru</surname> <given-names>T</given-names></string-name>, <string-name><surname>Fukui</surname> <given-names>M</given-names></string-name>, <string-name><surname>Okada</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mineoka</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yamazaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Tsujikawa</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet</article-title>. <source>Metab. Clin. Exp.</source> <year>2013</year>;<volume>62</volume>(<issue>6</issue>): <fpage>851</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.metabol.2012.12.007</pub-id>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Basaria</surname> <given-names>S</given-names></string-name>, <string-name><surname>Muller</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Carducci</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Egan</surname> <given-names>J</given-names></string-name>, <string-name><surname>Dobs</surname> <given-names>AS</given-names></string-name>. <article-title>Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy</article-title>. <source>Cancer</source>. <year>2006</year>;<volume>106</volume>(<issue>3</issue>): <fpage>581</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.21642</pub-id>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Lubik</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Gunter</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Hendy</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Locke</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Adomat</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal> <article-title>Insulin increases de novo steroidogenesis in prostate cancer cells</article-title>. <source>Cancer Res.</source> <year>2011</year>;<volume>71</volume>(<issue>17</issue>): <fpage>5754</fpage>&#x2013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.can-10-2470</pub-id>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Hsing</surname> <given-names>AW</given-names></string-name>, <string-name><surname>Sakoda</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Chua</surname> <given-names>S</given-names>, <suffix>Jr.</suffix></string-name> <article-title>Obesity, metabolic syndrome, and prostate cancer</article-title>. <source>Am. J. Clin. Nut.</source> <year>2007</year>;<volume>86</volume>(<issue>3</issue>): <fpage>s843</fpage>&#x2013;<lpage>57</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Grossmann</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wittert</surname> <given-names>G</given-names></string-name>. <article-title>Androgens, diabetes and prostate cancer</article-title>. <source>Endocrine-Related Cancer</source>. <year>2012</year>;<volume>19</volume>(<issue>5</issue>): <fpage>F47</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1530/erc-12-0067</pub-id>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Maugham</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>PB</given-names></string-name>, <string-name><surname>Crisp</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Philp</surname> <given-names>LK</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>ET</given-names></string-name>, <string-name><surname>Herington</surname> <given-names>AC</given-names></string-name>, <etal>et al.</etal> <article-title>Insights from engraftable immunodeficient mouse models of hyperinsulinaemia</article-title>. <source>Sci. Rep.</source> <year>2017</year>;<volume>7</volume>(<issue>1</issue>): <fpage>491</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-017-00443-x</pub-id>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Scott</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Kabbarah</surname> <given-names>O</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>M-C</given-names></string-name>, <string-name><surname>Ivanova</surname> <given-names>E</given-names></string-name>, <string-name><surname>Anagnostou</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal> <article-title>GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer</article-title>. <source>Nature</source>. <year>2009</year>; <volume>459</volume>: <fpage>1085</fpage>&#x2013;<lpage>1090</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="other"><collab>Diabetes Trial Unit</collab>. <article-title>The Oxford Centre for Diabetes EaM</article-title>. <source>HOMA Calculator University of Oxford</source>. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.dtu.ox.ac.uk/homacalculator/index.php">https://www.dtu.ox.ac.uk/homacalculator/index.php</ext-link>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Tong</surname> <given-names>J</given-names></string-name>, <string-name><surname>Davis</surname> <given-names>HW</given-names></string-name>, <string-name><surname>Summer</surname> <given-names>S</given-names></string-name>, <string-name><surname>Benoit</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Haque</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bidlingmaier</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans</article-title>. <source>Diabetes</source>. <year>2014</year>;<volume>63</volume>(<issue>7</issue>): <fpage>2309</fpage>&#x2013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.2337/db13-1598</pub-id>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Gortan Cappellari</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zanetti</surname> <given-names>M</given-names></string-name>, <string-name><surname>Semolic</surname> <given-names>A</given-names></string-name>, <string-name><surname>Vinci</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ruozi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Falcione</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Unacylated ghrelin reduces skeletal muscle reactive oxygen species generation and inflammation and prevents high-fat diet-induced hyperglycemia and whole-body insulin resistance in rodents</article-title>. <source>diabetes</source>. <year>2016</year>;<volume>65</volume>(<issue>4</issue>):<fpage>874</fpage>&#x2013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.2337/db15-1019</pub-id>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Banks</surname> <given-names>WA</given-names></string-name>, <string-name><surname>Tschop</surname> <given-names>M</given-names></string-name>, <string-name><surname>Robinson</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Heiman</surname> <given-names>ML</given-names></string-name>. <article-title>Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure</article-title>. <source>J. Pharmacol. Exper. Therap.</source> <year>2002</year>;<volume>302</volume>(<issue>2</issue>): <fpage>822</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1124/jpet.102.034827</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
</article>